Taking a Closer Look at Cancer As a Metabolic Disease : Oncology Times
An abstract is unavailable.
Related Articles
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
ADC Development in Ovarian Cancer: What’s Next for FRa and Beyond?
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.
Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Trifluridine/Tipiracil Benefits Stage IV CRC With Molecular Residual Disease
Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.
Burnout in US Oncologists Increased Over the Past 10 Years, Data Suggest
Burnout, emotional exhaustion, and depersonalization were more common in a 2023 survey than in a 2013 survey.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early…
Resilience of Adults With Cancer Comprises 4 Key Components – Oncology Nurse Advisor
An umbrella review of components of reliance among patients with cancer compared 20 instruments to find 3 that are ideal for these patients.
Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer
R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.
Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.